NasdaqGM - Nasdaq Real Time Price USD

Harmony Biosciences Holdings, Inc. (HRMY)

Compare
35.40 -0.22 (-0.63%)
As of 1:31 PM EDT. Market Open.
Loading Chart for HRMY
DELL
  • Previous Close 35.62
  • Open 35.42
  • Bid 35.39 x 100
  • Ask 35.54 x 100
  • Day's Range 35.19 - 35.84
  • 52 Week Range 18.61 - 39.26
  • Volume 45,668
  • Avg. Volume 366,607
  • Market Cap (intraday) 2.012B
  • Beta (5Y Monthly) 0.72
  • PE Ratio (TTM) 18.15
  • EPS (TTM) 1.95
  • Earnings Date Oct 29, 2024 - Nov 4, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 43.29

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

www.harmonybiosciences.com

246

Full Time Employees

December 31

Fiscal Year Ends

Recent News: HRMY

View More

Performance Overview: HRMY

Trailing total returns as of 8/28/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

HRMY
9.58%
S&P 500
17.22%

1-Year Return

HRMY
8.84%
S&P 500
26.91%

3-Year Return

HRMY
0.35%
S&P 500
23.99%

5-Year Return

HRMY
11.49%
S&P 500
65.68%

Compare To: HRMY

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: HRMY

View More

Valuation Measures

Annual
As of 8/27/2024
  • Market Cap

    2.02B

  • Enterprise Value

    1.86B

  • Trailing P/E

    18.27

  • Forward P/E

    21.83

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.18

  • Price/Book (mrq)

    3.76

  • Enterprise Value/Revenue

    2.84

  • Enterprise Value/EBITDA

    8.87

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    17.53%

  • Return on Assets (ttm)

    13.75%

  • Return on Equity (ttm)

    22.46%

  • Revenue (ttm)

    656.11M

  • Net Income Avi to Common (ttm)

    114.99M

  • Diluted EPS (ttm)

    1.95

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    346.91M

  • Total Debt/Equity (mrq)

    35.10%

  • Levered Free Cash Flow (ttm)

    159.8M

Research Analysis: HRMY

View More

Company Insights: HRMY

Research Reports: HRMY

View More

People Also Watch